Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Antonella Cosimati
Observed names:
A. Cosimati,
Cosimati, Antonella
Institution:
Sapienza University of Rome
Observed institutions:
Policlinico Umberto I,
Istituti di Ricovero e Cura a Carattere Scientifico,
Instituto Nazionale Tumori Regina Elena,
Sapienza University of Rome
ORCID:
0000-0002-2636-3198
Observed ORCID:
0000-0002-2636-3198
OpenAlex ID:
A5046978382
Malignant Transformation of Giant Cell Tumour of Bone: A Review of Literature and the Experience of a Referral Centre
2022
·
Sabrina Vari
, Federica Riva
, et al.
·
International Journal of Molecular Sciences
·
28
PDF
Bullous pemphigoid in elderly woman affected by non-small cell lung cancer treated with pembrolizumab: A case report and review of literature
2020
·
Antonella Cosimati
, Luigi Rossi
, et al.
·
Journal of Oncology Pharmacy Practice
·
20
Treatment Settings and Outcomes with Regorafenib and Trifluridine/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective Study
2023
·
Carlo Signorelli
, Maria Alessandra Calegari
, et al.
·
Current Oncology
·
15
PDF
Synchronous and Metachronous Metastatic Breast Cancer, with Different Histology and Opposite Immunophenotype, Treated with Combination of Chemotherapy, Anti-Her2, and Endocrine Therapy: A Case Report
2020
·
Giacomina Megaro
, Luigi Rossi
, et al.
·
Case Reports in Oncology
·
12
PDF
The impact of the COVID-19 pandemic on diagnosis and treatment of patients with soft tissue and bone sarcomas or aggressive benign musculoskeletal diseases: A single-center retrospective study (SarCorD study)
2022
·
Concetta Elisa Onesti
, Sabrina Vari
, et al.
·
Frontiers in Oncology
·
10
Rapid decline of humoral response to two doses of BNT162b2 vaccine in patients with solid cancer after six months: The urgent need of the additional dose!
2022
·
Vincenzo Di Noia
, Fulvia Pimpinelli
, et al.
·
European Journal of Cancer
·
10
PDF
Real-World Evidence of Regorafenib Dose Escalation Versus Fixed Dosing in Refractory Metastatic Colorectal Cancer: Results from the ReTrITA Study
2025
·
Carlo Signorelli
, Michele Basso
, et al.
·
Cancers
·
6
PDF
Survival Outcomes with Regorafenib and/or Trifluridine/Tipiracil Sequencing to Rechallenge with Third-Line Regimens in Metastatic Colorectal Cancer: A Multicenter Retrospective Real-World Subgroup Comparison from the ReTrITA Study
2024
·
Carlo Signorelli
, Maria Alessandra Calegari
, et al.
·
Current Oncology
·
6
PDF
Duration of humoral response to the third dose of BNT162b2 vaccine in patients with solid cancer: Is fourth dose urgently needed?
2022
·
Vincenzo Di Noia
, Fulvia Pimpinelli
, et al.
·
European Journal of Cancer
·
6
PDF
Redefining the Use of Regorafenib and Trifluridine/Tipiracil Without Bevacizumab in Refractory Metastatic Colorectal Cancer: Findings from the ReTrITA Study
2025
·
Carlo Signorelli
, Maria Alessandra Calegari
, et al.
·
Cancers
·
5
PDF
Quality of life and emotional distress in sarcoma patients diagnosed during COVID-19 pandemic: a supplementary analysis from the SarCorD study
2023
·
Concetta Elisa Onesti
, Sabrina Vari
, et al.
·
Frontiers in Psychology
·
3
PDF
Sequential treatment with regorafenib and trifluridine/tipiracil in later-line refractory metastatic colorectal cancer: A real-world multicenter retrospective study.
2023
·
Carlo Signorelli
, Marta Schirripa
, et al.
·
Journal of Clinical Oncology
·
3
Stunning Response with Low-Dose Enzalutamide after Abiraterone Acetate Failure in a Patient Diagnosed with Metastatic Castration-Resistant Prostate Cancer: A Case Report
2021
·
Luigi Rossi
, Giuseppe Cimino
, et al.
·
Case Reports in Oncology
·
3
PDF
Circulating Tumor DNA in Bladder Cancer: Current Clinical Evidence and Emerging Multi-Omics Perspectives—A Narrative Review
2026
·
Mariam Grazia Polito
, Luisana Sisca
, et al.
·
Cancers
·
2
Psoriasis induced by first‑line pembrolizumab in metastatic non‑small cell lung cancer: A case report
2023
·
Federica Gatti
, Gianluca Caruso
, et al.
·
Oncology Letters
·
2
PDF
Reply to the letter entitled: Re: The first report on Covid-19 vaccine refusal by patients with cancer in Italy: Early data from a single-institute survey
2021
·
Vincenzo Di Noia
, Federica Riva
, et al.
·
European Journal of Cancer
·
2
PDF
Impact of Adding Immune Checkpoint Inhibitors to Neoadjuvant Chemotherapy on pCR and Tumor Downstaging in Resectable Gastric Cancer: A Meta-Analysis
2026
·
Mariam Grazia Polito
, Luisana Sisca
, et al.
·
Cancers
·
1
PDF
On-Treatment Grade 3–4 Neutropenia and Clinical Outcomes with Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer: ReTrITA Real-World Evidence
2026
·
Carlo Signorelli
, Michele Basso
, et al.
·
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
·
1
PDF
Survival outcomes for right- versus left-sided colon cancer and rectal cancer in patients receiving regorafenib and/or trifluridine/tipiracil for refractory metastatic colorectal cancer: Findings from the multicenter retrospective ReTrITa study.
2025
·
Carlo Signorelli
, Maria Alessandra Calegari
, et al.
·
Journal of Clinical Oncology
·
1
PDF
Retrospective Correlation between First Drug Treatment Duration and Survival Outcomes in Sequential Treatment with Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer: A Real-World Subgroup Analysis
2023
·
Carlo Signorelli
, Mario Chilelli
, et al.
·
Cancers
·
1
PDF
29P Sarcoma patients need precision oncology: Is molecular tumor board the right way?
2022
·
A. Cosimati
, C.E. Onesti
, et al.
·
Annals of Oncology
·
1
PDF
Clinical Outcomes with Trifluridine/Tipiracil Versus Regorafenib in Octogenarian Patients with Refractory Metastatic Colorectal Cancer: Evidence from the ReTrITA Study
2026
·
Carlo Signorelli
, Annunziato Anghelone
, et al.
Adjuvant immune checkpoint inhibitors across solid tumors: a meta-analysis of phase II-III randomized trials
2026
·
Mariam Grazia Polito
, Luisana Sisca
, et al.
·
Frontiers in Oncology
PDF
Objective responses and survival outcomes by grade 3-4 neutropenia in refractory metastatic colorectal cancer treated with trifluridine/tipiracil: Real-world evidence from the ReTrITA study.
2026
·
Carlo Signorelli
, Michele Basso
, et al.
·
Journal of Clinical Oncology
Complete response in metastatic clear cell renal cell carcinoma following pembrolizumab–axitinib and subsequent nephrectomy: a Case Report
2026
·
Mariam Grazia Polito
, Davide Caruso
, et al.
·
Frontiers in Immunology
PDF
Show more works
View as search
Works count:
35
Citation count:
138
H-index:
6
I10-index:
6
Year
Topic
Type